ArticlebioRxiv : the preprint server for biology2023
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Florencia P Madorsky Rowdo, Gu Xiao, Galina F Khramtsova, John Nguyen, Olufunmilayo I Olopade, Rachel Martini, Brian Stonaker, Richard Boateng, Joseph K Oppong, Ernest K Adjei and 16 more
Open access · greenAbstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
26 authors at 7 institutions in 3 countries.
Florencia P Madorsky RowdoEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York, NY10021.ORCID 0000-0002-8504-1690 Gu XiaoThe Department of Biological Sciences Hunter College, Belfer Building, City University of New York, New York, NY10021.ORCID 0000-0001-8433-9121 Galina F KhramtsovaCenter for Clinical Cancer Genetics and Global Health and Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637.ORCID 000-0001-9625-1549 John NguyenEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York, NY10021.ORCID 0009-0007-0560-6684 Olufunmilayo I OlopadeCenter for Clinical Cancer Genetics and Global Health and Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637.ORCID 0000-0002-9936-1599 Esther ChengDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY.ORCID 0000-0002-0099-9438 Syed HodaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY.ORCID 0000-0002-1478-5115 Olivier ElementoEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York, NY10021.ORCID 0000-0002-8061-9617 Melissa B DavisEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York, NY10021.ORCID 0000-0002-6124-6923 M Laura MartinEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York, NY10021.ORCID 0000-0001-9359-5856 Jill BargonettiThe Department of Biological Sciences Hunter College, Belfer Building, City University of New York, New York, NY10021.ORCID 0000-0003-2692-0991 Cornell University · USKomfo Anokye Teaching Hospital · GHKwame Nkrumah University of Science and Technology · GHUniversity of Chicago · USCity University of New York · USIsland Hospital · USThe Graduate Center, CUNY · US
Funding
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MThe Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast CancerR01CA239603 · NCI · HUNTER COLLEGE · PI BARGONETTI, JILL E. · 2020 to 2024
$1.8MMolecular and Translational Oncology ResearchT32CA203702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLENIS, JOHN, GIANNAKAKOU, PARASKEVI · 2017 to 2021
$1.4MThe DARC side of Breast CancerR21CA210237 · NCI · UNIVERSITY OF GEORGIA · PI DAVIS, MELISSA B · 2017 to 2018
$386k5th Annual International Symposium: Improving Breast Cancer Management and OutcomesR13CA261076 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DAVIS, MELISSA B · 2021 to 2021
$20kNCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NCI NIH HHS R01 CA239603NCI NIH HHS R13 CA261076NCI NIH HHS R21 CA210237NCI NIH HHS T32 CA203702
6 · The paper itselfAbstract
Poly (ADP-ribose) polymerase inhibitors (PARPi) are used for patients with
Indexed as
DNA double-strand breaksmutant p53PARP inhibitorPatient-derived tumor organoidssynergistic cytotoxicity
Identifiers
PMID38076873
PMCPMC10705575
OpenAlexW4381856779
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390